5879-91-4

Upstream product

• 14088-05-2 2-Phenyl-6-methoxy-1,2,3,4-tetrahydronaphthalen-1-ol 
• 108-95-2 phenol 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 
• 1769-84-2 6-methoxy-2-phenyl-1-tetralone 
• 1729-38-0 1-(p-hydroxyphenyl)-6-methoxy-2-phenyl-3,4-dihydronaphthalene 
• 108-86-1 bromobenzene 
• 6793-92-6 p-benzyloxyphenylbromide 
• 308812-06-8 4-(4-(benzyloxy)phenyl)-7-methoxy-3-phenyl-1,2-dihydronaphthalene 
• 869006-52-0 4-(4-(benzyloxy)phenyl)-3-bromo-7-methoxy-1,2-dihydronaphthalene 

Downstream Products

• 72105-62-5 (5S,6R)-5-(4-Hydroxy-phenyl)-6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-ol 
• 180915-78-0 lasofoxifene 
• 22845-55-2 U₂₃₄₆₉ 
• 72105-64-7 3-{(5S,6R)-5-[4-(2,3-Dihydroxy-propoxy)-phenyl]-6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy}-propane-1,2-diol 
• 72105-61-4 3-[4-((1S,2R)-6-Hydroxy-2-phenyl-1,2,3,4-tetrahydro-naphthalen-1-yl)-phenoxy]-propane-1,2-diol 

Relevant academic research and scientific papers

ESTROGEN RECEPTOR TARGETING ANTAGONISTS

The present disclosure relates to compounds that act as antagonists via binding to the ER ligand binding domain non-covalently or covalently, or act as both antagonists and ER protein degraders, and the synthesis of the same. Further, the present disclosure teaches the utilization of such compounds in a treatment for proliferative diseases, including cancer, particularly breast cancer, and especially ER+ breast cancer.

ANTIESTROGEN COMPOUNDS

A genus of proteolysis-targeting chimeras (PROTACs)-type compounds/antiestrogens has now been found that act as selective estrogen receptor degraders (SERDs) and estrogen receptor antagonists by degrading and antagonizing ERa in breast cancer cells. The compounds are of the following genus: The compounds described herein exhibit anti-proliferative effects, and are potentially useful, alone or in combination with other therapies, for the treatment of breast cancer. In general, these compounds combine a tight binding ERa targeting ligand tethered to a recognition motif or degron. Once bound, the degron recruits destructive cellular components and the targeted receptor (i.e., ERa) is degraded (i.e., destroyed) or antagonized.

TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are tetrahydronaphthalene compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structura

An ortho-quinodimethane route to Lasofoxifene and U23469

Lasofoxifene, a third-generation selective estrogen receptor modulator, could be synthesized via regio-and stereoselective [4 + 2] cycloaddition between an ortho-quinodimethane and a borylalkene. This protocol was also applicable to the synthesis of antie

Selective estrogen receptor modulators

The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for the treatme

Antiestrogens and antiestrogen metabolites: Preparation of tritium-labeled (±)-cis-3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]-1,2-propanediol (U-23469) and characterization and synthesis of a biologically important metabolite

The Upjohn antiestrogen (±)-cis-3-[p-(1,2,3,4-tetrahydro-6-methoxy-2-phenyl-1-naphthyl)phenoxy]-1,2-propanediol (2b, U 23469) has been prepared in tritium-labeled form by reduction of an unsaturated dihydronaphthalene precursor with carrier-free tritium gas over a palladium catalyst followed by alkylation with 3-iodo-1,2-propanediol. After extensive chromatographic purification, the final material was obtained with a specific activity of 13 Ci/mmol and a radiochemical purity of 94%. In vivo studies with immature rats show that [3H]2b is slowly converted to a more polar metabolite that is selectively accumulated in the nuclear fraction of the uterus where it is bound to the estrogen receptor. Chromatographic comparisons indicate that this metabolite is a demethylated analogue, a compound that has an affinity for estrogen receptor more than 300 times greater than that of 2b. These studies suggest that the demethylated analogue may be a biologically important metabolite of 2b that is involved in the action of this antiestrogen.

Compounds and process for preparing the same

Cis and trans isomers of 1,2-diphenyl-1,2,3,4-tetrahydronaphthalenes, novel processes for the preparation thereof, and novel intermediates are disclosed herein. The novel 1,2-diphenyl-1,2,3,4-tetrahydronaphthalenes have utility as antifertility estrogenic, anti-estrogenic, anti-spermatogenic, cholesterol lowering and lipid normalizing agents.